Unknown Manufacturer
Pibrentasvir is a Hepatitis C NS5A inhibitor used to treat Hepatitis C.
Pibrentasvir is a Hepatitis C NS5A inhibitor used to treat Hepatitis C.
NS5A is a phosphoprotein that plays an essential role in replication, assembly and maturation of infectious viral proteins. The basal phosphorylated form of NS5A, which is maintained by C-terminal serine cluster, is key in ensuring its interaction with the viral capsid protein, or the core protein. By blocking this interaction, pibrentasvir inhibits the assembly of proteins and production of mature HCV particles . NS5A also interacts with viral and cellular proteins to form the HCV replicase complex, and supports the RNA replication of HCV .
Indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both .
7 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
